M P Dube

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy
    Michael P Dube
    Department of Medicine and Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 W 10th Street, Suite OPW 430, Indianapolis, IN 46202, USA
    Clin Chem Lab Med 43:947-52. 2005
  2. ncbi Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    Clin Infect Dis 45:120-6. 2007
  3. ncbi Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148
    Michael P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 11:1081-9. 2006
  4. ncbi Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
    AIDS 19:1807-18. 2005
  5. ncbi Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects
    Michael P Dube
    Department of Medicine and the Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 W 10th Street, Suite OPW 430, Indianapolis, IN 46202, USA
    Cardiovasc Toxicol 8:15-22. 2008
  6. ncbi Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult
    Michael P Dube
    Indiana University, Indianapolis, USA
    Clin Infect Dis 37:613-27. 2003
  7. ncbi Lipid abnormalities
    Michael Dube
    Indiana University School of Medicine, Wishard Memorial Hospital, Division of Infectious Diseases, Indianapolis, Indiana 46202 2879, USA
    Clin Infect Dis 36:S79-83. 2003
  8. ncbi Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy
    Michael P Dube
    Department of Medicine, Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Infect Dis 35:475-81. 2002
  9. ncbi Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients
    M P Dube
    Department of Medicine, Division of Infectious Diseases, University of Southern California School of Medicine, Los Angeles, California, U S A
    J Acquir Immune Defic Syndr 27:130-4. 2001
  10. ncbi Disorders of glucose metabolism in patients infected with human immunodeficiency virus
    M P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Infect Dis 31:1467-75. 2000

Research Grants

  1. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006

Detail Information

Publications18

  1. ncbi The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy
    Michael P Dube
    Department of Medicine and Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 W 10th Street, Suite OPW 430, Indianapolis, IN 46202, USA
    Clin Chem Lab Med 43:947-52. 2005
    ..001 from baseline; p=0.04 for difference between groups over time). When performed as in this study, frozen storage with central batch lactate analysis is appropriate for prospectively collected samples in multicenter trials...
  2. ncbi Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    Clin Infect Dis 45:120-6. 2007
    ..The effects of initiation of different antiretroviral regimens on testosterone levels and changes in fat-free mass have not been reported...
  3. ncbi Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148
    Michael P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 11:1081-9. 2006
    ..Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting...
  4. ncbi Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, Indiana, USA
    AIDS 19:1807-18. 2005
    ..To determine if particular components of antiretroviral drug regimens are associated with greater insulin resistance, dyslipidemia, and peripheral lipoatrophy...
  5. ncbi Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects
    Michael P Dube
    Department of Medicine and the Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, 1001 W 10th Street, Suite OPW 430, Indianapolis, IN 46202, USA
    Cardiovasc Toxicol 8:15-22. 2008
    ..This suggests that indinavir's effects on glucose metabolism are not directly related to indinavir-associated endothelial dysfunction. Studies of the vascular effects of newer protease inhibitors are needed...
  6. ncbi Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult
    Michael P Dube
    Indiana University, Indianapolis, USA
    Clin Infect Dis 37:613-27. 2003
  7. ncbi Lipid abnormalities
    Michael Dube
    Indiana University School of Medicine, Wishard Memorial Hospital, Division of Infectious Diseases, Indianapolis, Indiana 46202 2879, USA
    Clin Infect Dis 36:S79-83. 2003
    ..If pharmacologic therapy becomes necessary, the choices of lipid-lowering agents should be limited to agents with the least likelihood of adverse drug interactions...
  8. ncbi Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy
    Michael P Dube
    Department of Medicine, Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Infect Dis 35:475-81. 2002
    ..A trend toward insulin resistance appeared late in the study following weight gain, particularly of trunk fat, but without loss of limb fat...
  9. ncbi Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients
    M P Dube
    Department of Medicine, Division of Infectious Diseases, University of Southern California School of Medicine, Los Angeles, California, U S A
    J Acquir Immune Defic Syndr 27:130-4. 2001
    ..To determine whether initiation of antiretroviral therapy that includes the protease inhibitor indinavir causes insulin resistance or abnormal B-cell function in study subjects with HIV infection...
  10. ncbi Disorders of glucose metabolism in patients infected with human immunodeficiency virus
    M P Dube
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Infect Dis 31:1467-75. 2000
    ..It is therefore reasonable to recommend general measures to increase insulin sensitivity in all patients infected with HIV, such as weight reduction for obese persons and regular aerobic exercise...
  11. ncbi Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
    M P Dube
    Indiana University, Indianapolis, IN 46202, USA
    Clin Infect Dis 31:1216-24. 2000
    ..We propose that these patients undergo evaluation and treatment on the basis of existing guidelines for dyslipidemia, with the caveat that avoidance of interactions with antiretroviral agents is paramount...
  12. ncbi Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384
    Michael P Dube
    Division of Infectious Diseases, Indiana University, Indianapolis, USA
    J Acquir Immune Defic Syndr 45:508-14. 2007
    ..Long-term regional body fat outcomes have not been well described in randomized antiretroviral drug trials...
  13. ncbi Elevated blood pressure in subjects with lipodystrophy
    F R Sattler
    Division of Infectious Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
    AIDS 15:2001-10. 2001
    ..34; P = 0.052) in subjects with HIV. CONCLUSIONS: Elevated blood pressure may be linked to the metabolic disorders occurring in patients with HIV, as in the dysmetabolic syndrome...
  14. ncbi Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients
    S K Gupta
    Division of Infectious Diseases, Indiana University School of Medicine, Wishard Hospital, Indianapolis, IN 46202, USA
    Clin Nephrol 61:1-6. 2004
    ....
  15. ncbi Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group
    M P Dube
    University of Southern California School of Medicine, Los Angeles
    Clin Infect Dis 28:136-8. 1999
    ..Treatment of clarithromycin-resistant MAC bacteremia that emerges during clarithromycin-based treatment can decrease levels of bacteremia and transiently sterilize blood cultures...
  16. ncbi Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women
    Judith Currier
    Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 48:35-43. 2008
    ..HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional body fat and lipid levels is not well described...
  17. ncbi Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals
    Phyllis C Tien
    Department of Medicine, University of California, San Francisco, CA 94121, USA
    J Acquir Immune Defic Syndr 48:169-76. 2008
    ..Obesity is associated with hepatic steatosis, and ALT is a marker of steatosis in the general population...
  18. ncbi Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy
    Todd Hulgan
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 197:858-66. 2008
    ..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy...

Research Grants5

  1. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..